Bambusa Therapeutics (BBTX) investor relations material

Company overview and business model

• Clinical-stage biopharma developing long-acting bispecific antibodies for immunology and inflammation, combining validated pathways in single molecules designed for high-concentration SubQ delivery.

• Four programs span dermatology, respiratory disease, gastroenterology and autoimmune disease: BBT001 (IL-4Rα/IL-31), BBT002 (IL-4Rα/IL-5), BBT003 (TL1A/IL-23p19) and BBT004 (dual B-cell depletion).

• Worldwide program rights are held or obtainable under agreements with BioNTech Zhuhai; third-party engineering and manufacturing support remains central to development.

• Strategy prioritizes BBT001 and BBT002 clinical development, advancing BBT003 into the clinic by YE 2026, progressing BBT004, expanding indications and building late-stage and commercial capabilities.

Financial performance and metrics

• Net loss was $22.4M for H1 2026 vs. $14.7M in H1 2025; FY 2025 loss was $41.1M vs. $13.7M from inception through Dec. 2024.

• H1 2026 R&D expense was $20.6M vs. $11.9M in H1 2025; G&A was $3.4M vs. $3.6M.

• Cash, equivalents and marketable securities totaled $71.5M at June 30, 2026; preliminary Sept. 30, 2026 balance was $57.2M and was not expected to fund 12 months of operations on its own.

• At the assumed $16 IPO price, estimated net proceeds are $134.9M, or $155.8M with full overallotment; together with existing funds, management expects runway into late 2028.

• Audited statements and management disclosures cite substantial doubt about continuing as a going concern; no product revenue has been generated and losses are expected to continue.

Use of proceeds and capital allocation

• At the $16 assumed IPO price, approximately $90M is earmarked for BBT001, including the planned Phase 2b AD study; approximately $40M for BBT002, including a planned respiratory Phase 2b trial.

• Remaining proceeds are intended for BBT003 and BBT004 R&D, capital expenditures, working capital and public-company costs; management retains broad discretion over allocation.

• Proceeds plus existing cash are projected to fund operating expenses and capital needs into late 2028, but not all programs through regulatory approval; substantial additional capital will be required.